17 - Tissue and Medication Safety

Thursday, October 20, 2022

8:00 AM – 9:00 AM US ET

Location: 209 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Sapna Morris, MD

Medical Officer
Centers for Disease Control and Prevention
Atlanta, GA, United States

Disclosure(s): No financial relationships to disclose
Scott Brubaker

Director, Division of Human Tissues
FDA/CBER/Office of Tissues and Advanced Therapies
Silver Spring, MD, United States

Disclosure(s): No financial relationships to disclose

Slides

Faculty(s)

Noah Schwartz, MD (he/him/his)

Public Health Physician
Division of Tuberculosis Elimination
Centers for Disease Control and Prevention
Atlanta, GA, United States

Disclosure(s): No financial relationships to disclose

Slides
Kiran Perkins, MD, MPH

Lead, Outbreak Response Team, Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia, United States

Disclosure(s): No financial relationships to disclose

Slides
Scott Brubaker

Director, Division of Human Tissues
FDA/CBER/Office of Tissues and Advanced Therapies
Silver Spring, MD, United States

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Sapna B. Morris, MD: No financial relationships to disclose

Scott A. Brubaker: No financial relationships to disclose

Noah G. Schwartz, MD: No financial relationships to disclose

Kiran M. Perkins, MD, MPH: No financial relationships to disclose

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit

No CPE Credit Offered

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe risks associated use of human cell, tissue and cell or tissue-based products in various procedures;
discuss the current regulations and how human cell and tissue-based products are monitored and traced;
identify use of umbilical cord blood-derived products and risks associated with its use, and differentiate these products with stem cell products and their regulation

Presentations:

8:00 AM – 8:20 AM US ET

Spinal and Disseminated Tuberculosis Caused by Surgical Implantation of a Bone Tissue Product - 20 U.S. States, 2021
Speaker: Noah G. Schwartz, MD (he/him/his) – Centers for Disease Control and Prevention
8:20 AM – 8:40 AM US ET

Bacterial Infections Associated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies
Speaker: Kiran M. Perkins, MD, MPH – Centers for Disease Control and Prevention
8:40 AM – 9:00 AM US ET

Selections From the 21 CFR Part 1271 Regulations for Human Cells, Tissues and Cellular and Tissue-Based Products
Speaker: Scott A. Brubaker – FDA/CBER/Office of Tissues and Advanced Therapies